TRPC4 Antibody

What is the basic structure and function of TRPC4?

TRPC4 is a member of the Transient Receptor Potential (TRP) superfamily of ion channels, specifically belonging to the canonical TRPC subfamily. It functions as a non-selective cation channel with a molecular weight of approximately 100-120 kDa . TRPC4 regulates intracellular calcium levels through activation of signaling pathways mediated by Gq/11 and Gi/o-coupled receptors . The channel is involved in neurotransmission, neuronal excitability, and vascular endothelial cell function. Structurally, TRPC4 contains six transmembrane domains with both N- and C-termini located intracellularly, featuring a voltage-sensing-like (VSL) domain that serves as a binding site for several channel inhibitors .

Where is TRPC4 primarily expressed in the nervous system?

TRPC4 is highly expressed in specific regions of the nervous system. Studies have demonstrated substantial expression in:

• Trigeminal ganglia, particularly in neurons expressing CGRP

• Hippocampal CA1 region, where it modulates beta and low-gamma oscillations

• Cerebellum, notably in Purkinje cells and the molecular layer

• Astrocytes, including rat type I astrocytes and human U373 MG cells

Immunohistochemical staining techniques reveal that TRPC4 colocalizes with parvalbumin in some neuronal populations, suggesting possible roles in calcium signaling within these neurons .

How do I choose the optimal fixation and antigen retrieval methods for TRPC4 immunohistochemistry?

For optimal TRPC4 detection in tissue sections:

Fixation:

• For frozen sections: 4% paraformaldehyde (PFA) for 15-20 minutes provides good antigen preservation while maintaining tissue architecture

• For paraffin sections: 10% neutral buffered formalin for 24-48 hours followed by standard paraffin embedding

Antigen Retrieval:

• Heat-induced epitope retrieval (HIER) using TE buffer at pH 9.0 is recommended as the primary method

• Alternatively, citrate buffer at pH 6.0 can be effective for some antibody clones

• Optimize retrieval time (typically 10-20 minutes) based on specific tissue type and section thickness

Important considerations:

• Test both retrieval methods with your specific antibody clone

• Include positive control tissues (brain, kidney) in optimization experiments

• For double-labeling experiments, ensure compatibility of retrieval methods for both antibodies

What criteria should I consider when selecting a TRPC4 antibody for my research?

Selecting the appropriate TRPC4 antibody requires careful consideration of several technical factors:

Epitope Location:

• C-terminal antibodies (residues 943-958): Useful for detecting full-length TRPC4 and studying C-terminal interactions with regulatory proteins

• Middle region antibodies: Often provide better accessibility in native conformations

• Extracellular loop antibodies: Valuable for detecting surface expression and live-cell applications

Validation Status:

• Knockout validation: Antibodies tested in TRPC4 knockout tissues/cells provide highest confidence

• Blocking peptide validation: Confirms specificity through signal elimination with competing peptide

• Cross-reactivity: Verify specificity against other TRPC family members, particularly TRPC5 due to sequence homology

Application Compatibility:

Species Reactivity:
Most commercial antibodies show reactivity to human, mouse and rat TRPC4, with varying degrees of cross-reactivity to other species .

How can I validate the specificity of a TRPC4 antibody in my experimental system?

A comprehensive validation strategy includes:

Positive Controls:

• Well-characterized cell lines: HEK-293 cells (moderate expression), U87 cells (high expression)

• Tissue samples: Brain (particularly cerebellum), kidney

Negative Controls:

• TRPC4 knockdown/knockout systems: Use shRNA-TRPC4 cell lines for comparison

• Blocking peptide competition: Pre-incubation with immunizing peptide should eliminate specific signal

• Isotype control antibodies: Control for non-specific binding

Molecular Weight Verification:

• Expected molecular weight: 100-120 kDa

• Multiple bands may indicate splice variants, post-translational modifications, or degradation

Orthogonal Validation:

• Compare results from antibodies targeting different epitopes

• Correlate protein detection with mRNA expression (RT-qPCR)

• Use genetically tagged TRPC4 constructs as reference standards

What are the best practices for storing and handling TRPC4 antibodies to maintain their activity?

To preserve antibody functionality:

Storage Conditions:

• Temperature: Store at -20°C for long-term stability; avoid repeated freeze-thaw cycles

• Buffer composition: PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) provides optimal stability

• Aliquoting: For antibodies without BSA, aliquoting is recommended to minimize freeze-thaw cycles

Handling Recommendations:

• Thawing: Allow antibodies to thaw completely at 4°C before use

• Working dilutions: Prepare fresh and use within 24 hours

• Contamination prevention: Use sterile pipette tips and tubes

Stability Considerations:

• Shelf life: Typically one year after shipment when stored properly

• Conjugated antibodies: More sensitive to light exposure and temperature fluctuations

• Performance monitoring: Include positive controls in each experiment to track potential deterioration

What are the optimal conditions for detecting TRPC4 by Western blotting?

For successful Western blot detection of TRPC4:

Sample Preparation:

• Tissue samples: Membrane fractionation significantly improves detection compared to whole cell lysates

• Lysis buffer: RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors

• Protein denaturation: Heat samples at 70°C (not boiling) for 10 minutes to prevent aggregation

Electrophoresis and Transfer:

• Gel percentage: 8% SDS-PAGE provides optimal separation for the 100-120 kDa TRPC4 protein

• Transfer conditions: Wet transfer at 30V overnight at 4°C yields better results than rapid transfer protocols

• Membrane selection: PVDF membranes (0.45 μm) offer better retention of high molecular weight proteins

Detection Parameters:

• Blocking: 5% non-fat dry milk in TBST for 1 hour at room temperature

• Primary antibody incubation: 1:500-1:3000 dilution (antibody-dependent) overnight at 4°C

• Secondary antibody: HRP-conjugated anti-rabbit/mouse IgG at 1:5000-1:10000 for 1 hour at room temperature

• Signal development: Enhanced chemiluminescence with extended exposure times (1-5 minutes)

Controls and Validation:

• Positive control: Rat brain membranes, human PC3 cells, or LNCaP cells show reliable TRPC4 expression

• Specificity control: Pre-incubation of antibody with blocking peptide should eliminate specific bands

How can I optimize immunoprecipitation of TRPC4 for studying protein-protein interactions?

For effective TRPC4 immunoprecipitation:

Pre-IP Considerations:

• Starting material: Minimum 500 μg total protein from membrane-enriched fractions

• Pre-clearing: Incubate lysates with protein A/G beads for 1 hour to reduce non-specific binding

• Buffer composition: Use mild detergents (0.5-1% NP-40 or 0.5% Triton X-100) to preserve protein interactions

IP Protocol Optimization:

• Antibody amount: 6 μg per sample has been demonstrated effective for TRPC4 immunoprecipitation

• Incubation conditions: Overnight at 4°C with gentle rotation to maximize antigen-antibody binding

• Washing stringency: 3-5 washes with decreasing detergent concentrations to remove non-specific binding while preserving interactions

Interaction Analysis:

• Co-IP detection: Probe membranes for potential interaction partners after confirming TRPC4 pull-down

• Reciprocal IP: Confirm interactions by IP with antibodies against suspected binding partners

• Mass spectrometry: For unbiased identification of novel interaction partners

Validation Controls:

• Pre-immune serum: Use as negative control instead of IgG alone

• Input control: Load 5-10% of pre-IP sample to confirm target protein presence

• Known interactors: Include detection of established binding partners (e.g., calmodulin for TRPC4)

What are the critical parameters for immunohistochemical detection of TRPC4 in brain tissue sections?

Tissue Preparation:

• Fixation: 4% PFA for 24 hours optimally preserves epitopes

• Sectioning: 30-40 μm floating sections for adult brain tissue

• Antigen retrieval: TE buffer (pH 9.0) or citrate buffer (pH 6.0) at 95°C for 15-20 minutes

Immunostaining Protocol:

• Blocking: 10% normal serum with 0.3% Triton X-100 for 2 hours at room temperature

• Primary antibody: 1:20-1:200 dilution (antibody-dependent) for 48-72 hours at 4°C

• Secondary antibody: Fluorophore-conjugated secondary antibodies at 1:500 for 2 hours at room temperature

• Nuclear counterstain: DAPI at 1:1000 for 10 minutes

Visualization Parameters:

• Confocal settings: Sequential scanning to prevent bleed-through

• Exposure settings: Establish using positive control tissues

• Resolution: Use high-magnification (63x-100x) oil immersion objectives for subcellular localization

Region-Specific Considerations:

• Cerebellum: TRPC4 is prominently expressed in Purkinje cells and the molecular layer

• Hippocampus: CA1 region shows substantial TRPC4 expression

• Trigeminal ganglia: Co-localization with CGRP should be assessed in pain/migraine studies

How can I use TRPC4 antibodies to investigate its role in migraine and pain processing?

Studies have demonstrated TRPC4's involvement in migraine pathophysiology and pain signaling, providing several experimental approaches:

Tissue-Specific Expression Analysis:

• Trigeminal ganglia examination: TRPC4 is highly expressed in trigeminal neurons that mediate both itch and pain responses

• DiI labeling combined with immunostaining: To identify TRPC4-expressing cutaneous nerves innervating specific regions like the cheek

• Colocalization studies: Examine TRPC4 and CGRP co-expression patterns in sensory neurons, as TRPC4 activation regulates CGRP release

Functional Investigation Methods:

• Cheek injection model: Can be employed to measure both pain and itch-related behaviors in response to TRPC4 agonists (e.g., Englerin A)

• Nitroglycerin (NTG)-induced migraine model: For assessing TRPC4's role in migraine-like behaviors and evaluating effects of TRPC4 antagonists (e.g., ML204)

• CGRP measurements: Quantify plasma CGRP levels following TRPC4 activation/inhibition to establish mechanistic links to migraine

Therapeutic Target Validation:

• Pharmacological inhibition: Compare effects of specific TRPC4 antagonists on pain behaviors and CGRP release

• Genetic approaches: Assess pain phenotypes in TRPC4 knockdown/knockout models versus controls

• Translational relevance: Correlate findings with human migraine biomarkers

What methodologies can be employed to study TRPC4's role in viral infections like Zika?

Recent research has revealed TRPC4's involvement in Zika virus (ZIKV) pathogenesis, suggesting several investigative approaches:

Expression Analysis During Infection:

• Temporal expression profiling: Monitor TRPC4 RNA and protein levels at different timepoints post-infection (48h, 72h)

• Correlation analysis: Establish statistical correlation between TRPC4 and viral protein (e.g., ZIKV-NS1) expression

• Cell-type specificity: Compare TRPC4 upregulation across different cell types (BHK cells, U87 cells, neurons)

Mechanistic Investigation:

• TRPC4 knockdown studies: Use shRNA targeting TRPC4 to assess effects on viral replication and cell survival

• Pharmacological inhibition: Apply specific TRPC4 channel inhibitors (e.g., HC-070) to infected cells to evaluate viral production

• Calcium imaging: Monitor changes in Ca²⁺ influx during infection and its relationship to viral replication

In Vivo Validation:

• Animal models: Utilize interferon receptor-deficient adult A129 mice for studying TRPC4-ZIKV relationships

• Brain-specific analysis: Perform immunofluorescence analysis of adult mouse brain regions to localize TRPC4 upregulation in ZIKV-infected areas

• Therapeutic potential: Test TRPC4 inhibitors for ability to reduce viral load or symptoms in animal models

How can structural data inform the development of TRPC4-targeted therapeutics?

Cryo-EM structures of TRPC4 with various inhibitors provide valuable insights for rational drug design:

Key Structural Features:

• Ligand binding pocket: Located within the voltage sensing-like (VSL) domain, TRP helix, and re-entrant loop

• Binding site characteristics: Enclosed by the four helices S1 to S4 of the VSL domain

• Inhibitor interactions: Pyridazinone-based compounds (GFB-8438, GFB-9289, GFB-8749) bind to the same region but with distinct conformational impacts

Structure-Guided Approaches:

• Pharmacophore modeling: Use the common structural features of known inhibitors to design new compounds

• Structure-activity relationship (SAR) studies: Systematically modify chemical scaffolds to improve potency/selectivity

• Molecular dynamics simulations: Predict binding modes and affinities of candidate compounds

Experimental Validation Methods:

• Binding assays: Measure direct interaction of compounds with purified TRPC4 protein

• Electrophysiology: Patch-clamp recordings to assess functional effects on channel activity

• Specificity profiling: Test compound effects across TRPC subfamily members to ensure selectivity

What are common issues in TRPC4 Western blotting and how can they be resolved?

Problem: No signal or weak signal
Potential causes and solutions:

• Insufficient protein: Increase loading amount to 50-100 μg per lane

• Inadequate transfer: Extend transfer time or reduce voltage for high molecular weight proteins

• Degraded antibody: Test a new antibody aliquot or lot

• Low TRPC4 expression: Enrich membrane fractions before loading

Problem: Multiple bands or unexpected molecular weight
Potential causes and solutions:

• Splice variants: TRPC4 has multiple isoforms; compare with tissue-specific positive controls

• Degradation: Add additional protease inhibitors and keep samples cold

• Post-translational modifications: Treat with phosphatases or glycosidases to confirm modifications

• Non-specific binding: Increase blocking time/concentration or try alternative blocking reagents

Problem: High background
Potential causes and solutions:

• Insufficient blocking: Extend blocking time to 2 hours or overnight

• Secondary antibody concentration: Dilute secondary antibody further (1:10000 or greater)

• Membrane overexposure: Reduce exposure time during imaging

• Wash stringency: Increase number and duration of wash steps

How can I effectively analyze TRPC4 colocalization with other proteins in immunofluorescence studies?

Acquisition Parameters:

• Optical sectioning: Use confocal microscopy with 0.5-1 μm z-steps

• Channel settings: Carefully adjust to prevent bleed-through between fluorophores

• Resolution: Nyquist sampling criteria should be met for accurate colocalization analysis

• Controls: Include single-labeled samples to set thresholds and confirm channel separation

Quantitative Analysis Methods:

Interpretation Guidelines:

• Statistical validation: Compare experimental versus random colocalization (through pixel scrambling)

• Biological relevance: Correlate colocalization metrics with functional outcomes

• Resolution limits: Acknowledge that confocal microscopy cannot resolve proteins within 200-250 nm

Advanced Approaches:

• Super-resolution microscopy: Techniques like STORM or STED provide higher resolution (20-100 nm)

• Proximity ligation assay (PLA): Detects proteins within 40 nm of each other

• FRET analysis: For detecting direct molecular interactions (<10 nm)

How should I interpret contradictory results between TRPC4 mRNA and protein expression levels?

Potential Causes of Discrepancy:

• Post-transcriptional regulation: miRNAs may suppress translation without affecting mRNA levels

• Protein stability differences: Variations in protein half-life can cause discordance with mRNA levels

• Detection sensitivity: Differences in assay sensitivities between RT-qPCR and antibody-based methods

• Temporal dynamics: Time lag between transcription and translation, especially during rapid responses

Verification Strategies:

• Time-course analysis: Sample at multiple timepoints to capture transcription-translation dynamics

• Protein stability assessment: Treat with cycloheximide to inhibit protein synthesis and measure degradation rate

• Multiple antibodies: Use antibodies targeting different epitopes to confirm protein expression patterns

• Single-cell analysis: Techniques like FISH combined with immunostaining to correlate mRNA and protein in the same cells

Data Integration Approaches:

• Normalization methods: Apply appropriate normalization to both mRNA and protein data

• Correlation analysis: Calculate Spearman's rank correlation coefficients between datasets

• Pathway analysis: Consider regulatory factors that might explain discrepancies

• Mathematical modeling: Develop models incorporating transcription, translation, and degradation rates